Florquinitau F18
- Generic Name
- Florquinitau F18
Lantheus' Alzheimer's Radiodiagnostic MK-6240 Achieves Pivotal Study Success, NDA Filing Planned
• Lantheus Holdings announced its F18-labeled tau PET radiodiagnostic MK-6240 successfully met co-primary endpoints in two pivotal studies, demonstrating both sensitivity and specificity for detecting tau pathology in Alzheimer's disease.
• The company plans to file a New Drug Application with the FDA in Q3 2025, potentially advancing a diagnostic tool that targets neurofibrillary tangles, a key hallmark of Alzheimer's disease.
• If approved, MK-6240 could significantly impact Alzheimer's management by enabling earlier detection, patient staging, therapy selection, and monitoring, with the U.S. Alzheimer's radiodiagnostic market projected to reach $1.5 billion by 2030.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath